Logo image of SERA

SERA PROGNOSTICS INC-A (SERA) Stock Fundamental Analysis

NASDAQ:SERA - Nasdaq - US81749D1072 - Common Stock - Currency: USD

3.98  -0.47 (-10.56%)

Fundamental Rating

2

SERA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. SERA may be in some trouble as it scores bad on both profitability and health. SERA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SERA had negative earnings in the past year.
SERA had a negative operating cash flow in the past year.
In the past 5 years SERA always reported negative net income.
In the past 5 years SERA always reported negative operating cash flow.
SERA Yearly Net Income VS EBIT VS OCF VS FCFSERA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

SERA has a Return On Assets of -40.81%. This is comparable to the rest of the industry: SERA outperforms 55.22% of its industry peers.
With a decent Return On Equity value of -59.00%, SERA is doing good in the industry, outperforming 60.71% of the companies in the same industry.
Industry RankSector Rank
ROA -40.81%
ROE -59%
ROIC N/A
ROA(3y)-33.26%
ROA(5y)-60.96%
ROE(3y)-40.53%
ROE(5y)-214%
ROIC(3y)N/A
ROIC(5y)N/A
SERA Yearly ROA, ROE, ROICSERA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

With a decent Gross Margin value of 21.28%, SERA is doing good in the industry, outperforming 74.69% of the companies in the same industry.
SERA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SERA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2%
GM growth 5YN/A
SERA Yearly Profit, Operating, Gross MarginsSERA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -20K -40K -60K

More info and screens

3

2. Health

2.1 Basic Checks

SERA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SERA has more shares outstanding
The debt/assets ratio for SERA has been reduced compared to a year ago.
SERA Yearly Shares OutstandingSERA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
SERA Yearly Total Debt VS Total AssetsSERA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of -2.20, we must say that SERA is in the distress zone and has some risk of bankruptcy.
SERA's Altman-Z score of -2.20 is in line compared to the rest of the industry. SERA outperforms 51.33% of its industry peers.
SERA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
SERA's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. SERA outperforms 49.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.2
ROIC/WACCN/A
WACC9.4%
SERA Yearly LT Debt VS Equity VS FCFSERA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

SERA has a Current Ratio of 2.11. This indicates that SERA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.11, SERA is not doing good in the industry: 75.22% of the companies in the same industry are doing better.
SERA has a Quick Ratio of 2.11. This indicates that SERA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.11, SERA is doing worse than 73.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 2.11
SERA Yearly Current Assets VS Current LiabilitesSERA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

SERA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.85%, which is quite good.
The Revenue for SERA has decreased by -71.52% in the past year. This is quite bad
Measured over the past years, SERA shows a very strong growth in Revenue. The Revenue has been growing by 116.87% on average per year.
EPS 1Y (TTM)18.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.35%
Revenue 1Y (TTM)-71.52%
Revenue growth 3Y116.87%
Revenue growth 5YN/A
Sales Q2Q%-30.95%

3.2 Future

SERA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.77% yearly.
Based on estimates for the next years, SERA will show a very strong growth in Revenue. The Revenue will grow by 269.44% on average per year.
EPS Next Y14.27%
EPS Next 2Y5.86%
EPS Next 3Y2.77%
EPS Next 5YN/A
Revenue Next Year-69.01%
Revenue Next 2Y213.99%
Revenue Next 3Y269.44%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SERA Yearly Revenue VS EstimatesSERA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
SERA Yearly EPS VS EstimatesSERA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SERA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SERA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SERA Price Earnings VS Forward Price EarningsSERA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SERA Per share dataSERA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.86%
EPS Next 3Y2.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SERA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERA PROGNOSTICS INC-A

NASDAQ:SERA (2/11/2025, 1:15:22 PM)

3.98

-0.47 (-10.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners71.46%
Inst Owner Change-66.12%
Ins Owners5.25%
Ins Owner Change-4.42%
Market Cap134.40M
Analysts85
Price TargetN/A
Short Float %2.95%
Short Ratio7.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.28%
Min EPS beat(2)-6.95%
Max EPS beat(2)7.51%
EPS beat(4)3
Avg EPS beat(4)3.88%
Min EPS beat(4)-6.95%
Max EPS beat(4)9.22%
EPS beat(8)7
Avg EPS beat(8)10.73%
EPS beat(12)9
Avg EPS beat(12)7.78%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-69.43%
Min Revenue beat(2)-72.32%
Max Revenue beat(2)-66.55%
Revenue beat(4)0
Avg Revenue beat(4)-64.62%
Min Revenue beat(4)-100%
Max Revenue beat(4)-19.61%
Revenue beat(8)2
Avg Revenue beat(8)-43.36%
Revenue beat(12)2
Avg Revenue beat(12)-39.13%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-87.5%
Revenue NY rev (1m)4.76%
Revenue NY rev (3m)-56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1429.84
P/FCF N/A
P/OCF N/A
P/B 2.46
P/tB 2.5
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS1.62
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.81%
ROE -59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.28%
FCFM N/A
ROA(3y)-33.26%
ROA(5y)-60.96%
ROE(3y)-40.53%
ROE(5y)-214%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2%
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 127.16%
Cap/Sales 1125.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.11
Quick Ratio 2.11
Altman-Z -2.2
F-Score3
WACC9.4%
ROIC/WACCN/A
Cap/Depr(3y)105.05%
Cap/Depr(5y)68.68%
Cap/Sales(3y)653.14%
Cap/Sales(5y)546.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.35%
EPS Next Y14.27%
EPS Next 2Y5.86%
EPS Next 3Y2.77%
EPS Next 5YN/A
Revenue 1Y (TTM)-71.52%
Revenue growth 3Y116.87%
Revenue growth 5YN/A
Sales Q2Q%-30.95%
Revenue Next Year-69.01%
Revenue Next 2Y213.99%
Revenue Next 3Y269.44%
Revenue Next 5YN/A
EBIT growth 1Y12.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.77%
OCF growth 3YN/A
OCF growth 5YN/A